Debate: Prasugrel rather than ticagrelor is the preferred treatment for NSTE-ACS patients who proceed to PCI and pretreatment should not be performed in patients planned for an early invasive strategy

Filippo Crea

doi:10.1093/eurheartj/ehab277

Debate: Prasugrel rather than ticagrelor is the preferred treatment for NSTE-ACS patients who proceed to PCI and pretreatment should not be performed in patients planned for an early invasive strategy

Filippo Crea

Risultato della ricerca: Contributo in rivista › Articolo

Abstract

N/A

Lingua originale	Inglese
pagine (da-a)	2973-2985
Numero di pagine	13
Rivista	European Heart Journal
Volume	42
DOI	https://doi.org/10.1093/eurheartj/ehab277
Stato di pubblicazione	Pubblicato - 2021

Keywords

Clopidogrel
Humans
Percutaneous Coronary Intervention
Prasugrel Hydrochloride
Purinergic P2Y Receptor Antagonists
Ticagrelor

Accesso al documento

10.1093/eurheartj/ehab277

Altri file e collegamenti

Link a IRIS PubliCatt

Cita questo

@article{20e7f3f34dd64c668787d9e7f63b11f4,

title = "Debate: Prasugrel rather than ticagrelor is the preferred treatment for NSTE-ACS patients who proceed to PCI and pretreatment should not be performed in patients planned for an early invasive strategy",

abstract = "N/A",

keywords = "Clopidogrel, Humans, Percutaneous Coronary Intervention, Prasugrel Hydrochloride, Purinergic P2Y Receptor Antagonists, Ticagrelor, Clopidogrel, Humans, Percutaneous Coronary Intervention, Prasugrel Hydrochloride, Purinergic P2Y Receptor Antagonists, Ticagrelor",

author = "Filippo Crea",

year = "2021",

doi = "10.1093/eurheartj/ehab277",

language = "English",

volume = "42",

pages = "2973--2985",

journal = "European Heart Journal",

issn = "0195-668X",

publisher = "Oxford University Press",

}

TY - JOUR

T1 - Debate: Prasugrel rather than ticagrelor is the preferred treatment for NSTE-ACS patients who proceed to PCI and pretreatment should not be performed in patients planned for an early invasive strategy

AU - Crea, Filippo

PY - 2021

Y1 - 2021

N2 - N/A

AB - N/A

KW - Clopidogrel

KW - Humans

KW - Percutaneous Coronary Intervention

KW - Prasugrel Hydrochloride

KW - Purinergic P2Y Receptor Antagonists

KW - Ticagrelor

KW - Clopidogrel

KW - Humans

KW - Percutaneous Coronary Intervention

KW - Prasugrel Hydrochloride

KW - Purinergic P2Y Receptor Antagonists

KW - Ticagrelor

UR - http://hdl.handle.net/10807/204471

U2 - 10.1093/eurheartj/ehab277

DO - 10.1093/eurheartj/ehab277

M3 - Article

SN - 0195-668X

VL - 42

SP - 2973

EP - 2985

JO - European Heart Journal

JF - European Heart Journal

ER -

Debate: Prasugrel rather than ticagrelor is the preferred treatment for NSTE-ACS patients who proceed to PCI and pretreatment should not be performed in patients planned for an early invasive strategy

Abstract

Keywords

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo